|
|
Post by therealisaching on Aug 22, 2016 8:51:08 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 22, 2016 8:53:38 GMT -5
I win by a minute. I out ran the outsulin guy lol
|
|
|
|
Post by nylefty on Aug 22, 2016 9:00:44 GMT -5
FAQ
August 2016
Below please find answers and guidance to questions received at ir@mannkindcorp.com. Repeat questions of the same topic are combined, and similarly themed questions are grouped together.
What is the status of the Sanofi termination, including the final tally of monetary obligations in each direction?
The Sanofi collaboration agreement terminated on April 5, 2016. At that time, we signed a transition agreement, whereby Sanofi agreed to supply Afrezza to the market until such time as we were able to do so ourselves, or October 1, 2016, whichever came first. As announced on August 1, we now have MannKind branded product in commercial channels and available for purchase, so the agreement with Sanofi is winding down.
We expect that the third quarter of 2016 will be the final quarter of our profit and loss sharing arrangement with Sanofi; however, certain aspects of our relationship with Sanofi will continue beyond this date. As examples, our indebtedness under the loan facility with Sanofi will not mature until August 2024 and Sanofi’s obligations under the “Insulin put” will continue until Sanofi’s share of our current and future insulin purchases accumulates to $50 million. Under the terms negotiated with Sanofi, another payment from them is anticipated late this year, and payments will continue to be made periodically for at least the next couple of years.
What are your plans for international partnering (including timing)? What about the “easy” targets, international markets that accept FDA regulation?
While discussions with international partners are ongoing, we are not able to project a timeline for any
deal. We are necessarily concentrating on the US market first, both because of limited bandwidth and
because it is unlikely that an attractive international deal would be finalized before we are able to
demonstrate the viability of the product in the US.
One of the major faults in the Sanofi launch was the pricing of Afrezza, it was too high, is that already solved?
At the time Sanofi initially launched Afrezza, it carried a significant price premium compared to injected
rapid acting analogs. Since then, those other insulins have raised their prices multiple times, while
Afrezza has kept the same pricing, or even reduced pricing on new product configurations. As a result,
we no longer believe that pricing is an impediment.
What are the actual script numbers and will you forecast sales?
While we have no intention of forecasting sales in the near term, we are investigating our ability to post
prescription data on our web site or similar accessible portal under the terms of our subscription
agreement with the provider of this data.
I was very pleased with the announcement of diabetes centers in the January strategy outlook, still waiting. I know it was not a MannKind initiative but is the idea still ongoing and why the delay?
You are correct that these centers are not affiliated with MannKind in any way. While we think they
make a lot of sense, we are not privy to all the details behind delays experienced in their opening. We
have received unsubstantiated reports that complications arose with plans to open the first centers in
New Jersey and the decision was made to instead open them in California. But we do not have further
information at this time.
I have noticed that your web page is rather out of date. Are there any plans to update it with new content?
We have recently redesigned and updated our corporate website as well as the separate dedicated
website for Afrezza. Both are going through final review and should be rolled out very soon.
|
|
|
|
Post by saxcmann on Aug 22, 2016 9:07:19 GMT -5
I didn't know this...
Under the terms negotiated with Sanofi, another
Payment from them is anticipated late this year, and payments will continue to be made periodically for at least the next couple of years.
|
|
|
|
Post by kbrion77 on Aug 22, 2016 9:15:07 GMT -5
I didn't know this... Under the terms negotiated with Sanofi, another Payment from them is anticipated late this year, and payments will continue to be made periodically for at least the next couple of years. So $9.2mm received in Q2-16, maybe another $9-$10mm received in Q4-16? Wonder if they negotiated semi-annual payments. So a possible RLS milestone and another Sanofi put in Q4-16 could give them another quarter worth of cash next year. |
|
|
|
Post by centralcoastinvestor on Aug 22, 2016 9:28:23 GMT -5
I appreciate the communication from management. Under Hakan, I don't think we would be informed as much as Matt is doing.
|
|
|
|
Post by flatrock on Aug 22, 2016 10:42:38 GMT -5
They think pricing is not an impediment? With some competing insulins costing next to nothing due to insurance coverage, how could pricing not be an impediment?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 22, 2016 10:58:47 GMT -5
They think pricing is not an impediment? With some competing insulins costing next to nothing due to insurance coverage, how could pricing not be an impediment? Ask them in an email and let us know the response |
|
|
|
Post by anderson on Aug 22, 2016 11:22:38 GMT -5
They think pricing is not an impediment? With some competing insulins costing next to nothing due to insurance coverage, how could pricing not be an impediment? Uh that isnt a pricing issue if they cost nearly the same whole sale that is an insurance coverage issue. Just like obamacare(health insurance) isnt health care. Apples are not oranges but people keep trying to say they are...... |
|
|
|
Post by flatrock on Aug 22, 2016 11:26:09 GMT -5
They think pricing is not an impediment? With some competing insulins costing next to nothing due to insurance coverage, how could pricing not be an impediment? Uh that isnt a pricing issue if they cost nearly the same whole sale that is an insurance coverage issue. Just like obamacare(health insurance) isnt health care. Apples are not oranges but people keep trying to say they are...... I'm getting confused again. I thought pricing was the insurance issue and that new pricing would improve the insurance situation. |
|
|
|
Post by anderson on Aug 22, 2016 11:47:20 GMT -5
|
|
|
|
Post by obamayoumama on Aug 22, 2016 11:58:08 GMT -5
They think pricing is not an impediment? With some competing insulins costing next to nothing due to insurance coverage, how could pricing not be an impediment? Ask them in an email and let us know the response If $15.00 a month on a co pay is too much for your health, ouch! |
|
|
|
Post by gamblerjag on Aug 22, 2016 12:05:41 GMT -5
I too appreciate the FAQ update. Still wonder why that Reuter's article that came out in January 2016 about MNKD possibly looking to sell. I never believed it to be true and Reuters usually is one of the better resources.. I guess they just got false info.
From 1/27/16 MannKind reportedly looking to sell itself |
|
|
|
Post by flatrock on Aug 22, 2016 12:18:51 GMT -5
Ask them in an email and let us know the response If $15.00 a month on a co pay is too much for your health, ouch! There isn't much profit margin in $15 a month. |
|
|
|
Post by mnkdfann on Aug 22, 2016 12:20:26 GMT -5
I too appreciate the FAQ update. Still wonder why that Reuter's article that came out in January 2016 about MNKD possibly looking to sell. I never believed it to be true and Reuters usually is one of the better resources.. I guess they just got false info.
From 1/27/16 MannKind reportedly looking to sell itself Assuming it was accurate reporting, Reuters really only said Mannkind was looking into a sale. Maybe it was. Maybe it was one of several options being looked at. Maybe there was no interest among potential buyers. Just because a sale did not happen does not mean the info was not accurate at the time. At least, that's how I look at it. |
|
